MedTrace Logo

Interventional Study of Wellbutrin XL in Major Depressive Disorder With Atypical Features

NCT01477931 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 50

Last updated 2011-11-23

No results posted yet for this study

Summary

The aims of this study are 1) to examine the clinical utility of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with Major Depressive Disorder (MDD) with atypical features; 2) to evaluate the tolerability of bupropion hydrochloride extended release (Wellbutrin XL®) in patients with MDD with atypical features.

Conditions

  • Depressive Disorder, Major

Interventions

DRUG

Bupropion extended release

300mg once a daily, PO, 8weeks

Sponsors & Collaborators

Principal Investigators

  • Chi-Un Pae, MD · Department of Psychiatry, Bucheon St.Mary's Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
20 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-11-30
Primary Completion
2011-07-31
Completion
2011-09-30

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01477931 on ClinicalTrials.gov